Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 19 | 2025 | 661 | 1.720 |
Why?
|
| Analgesics, Opioid | 11 | 2025 | 483 | 1.140 |
Why?
|
| Dietary Supplements | 3 | 2021 | 222 | 1.070 |
Why?
|
| Pharmacy | 2 | 2022 | 18 | 1.050 |
Why?
|
| Education, Pharmacy | 5 | 2020 | 17 | 0.960 |
Why?
|
| Complementary Therapies | 2 | 2018 | 56 | 0.840 |
Why?
|
| Students, Pharmacy | 3 | 2020 | 12 | 0.820 |
Why?
|
| Vaccines | 1 | 2022 | 95 | 0.710 |
Why?
|
| Homes for the Aged | 5 | 2020 | 157 | 0.710 |
Why?
|
| Pharmacists | 7 | 2020 | 123 | 0.700 |
Why?
|
| Drug Utilization | 6 | 2021 | 208 | 0.570 |
Why?
|
| Hospice Care | 1 | 2018 | 62 | 0.570 |
Why?
|
| Evidence-Based Medicine | 3 | 2010 | 442 | 0.560 |
Why?
|
| Palliative Care | 2 | 2020 | 214 | 0.550 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2021 | 208 | 0.470 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2020 | 692 | 0.470 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 681 | 0.460 |
Why?
|
| Pain | 5 | 2023 | 397 | 0.460 |
Why?
|
| Medicare | 10 | 2023 | 601 | 0.430 |
Why?
|
| Aged | 28 | 2025 | 13423 | 0.420 |
Why?
|
| Humans | 48 | 2025 | 59424 | 0.410 |
Why?
|
| United States | 22 | 2025 | 7429 | 0.400 |
Why?
|
| Skilled Nursing Facilities | 5 | 2021 | 83 | 0.390 |
Why?
|
| Aspirin | 2 | 2011 | 167 | 0.390 |
Why?
|
| Aged, 80 and over | 19 | 2025 | 5126 | 0.380 |
Why?
|
| Atrial Fibrillation | 4 | 2023 | 805 | 0.380 |
Why?
|
| Activities of Daily Living | 4 | 2021 | 289 | 0.370 |
Why?
|
| Electronic Prescribing | 1 | 2011 | 10 | 0.370 |
Why?
|
| Stroke | 4 | 2023 | 1128 | 0.370 |
Why?
|
| Epilepsy | 2 | 2023 | 105 | 0.350 |
Why?
|
| Pain Management | 4 | 2024 | 146 | 0.350 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 163 | 0.340 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 789 | 0.340 |
Why?
|
| Professional Role | 3 | 2016 | 39 | 0.330 |
Why?
|
| Vitamins | 1 | 2010 | 74 | 0.330 |
Why?
|
| Integrative Medicine | 2 | 2021 | 27 | 0.320 |
Why?
|
| Drug Therapy | 2 | 2010 | 52 | 0.310 |
Why?
|
| Patient Selection | 1 | 2011 | 465 | 0.310 |
Why?
|
| Computers, Handheld | 2 | 2005 | 38 | 0.310 |
Why?
|
| Physicians | 2 | 2011 | 440 | 0.300 |
Why?
|
| Primary Health Care | 2 | 2011 | 649 | 0.300 |
Why?
|
| Female | 26 | 2025 | 30753 | 0.290 |
Why?
|
| Attitude of Health Personnel | 2 | 2011 | 551 | 0.290 |
Why?
|
| Chronic Pain | 3 | 2024 | 134 | 0.290 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2017 | 142 | 0.290 |
Why?
|
| Malabsorption Syndromes | 1 | 2007 | 3 | 0.280 |
Why?
|
| Professional-Patient Relations | 1 | 2008 | 126 | 0.270 |
Why?
|
| Gastric Bypass | 1 | 2007 | 74 | 0.260 |
Why?
|
| Delirium | 2 | 2025 | 54 | 0.260 |
Why?
|
| Algorithms | 1 | 2011 | 977 | 0.250 |
Why?
|
| Anticonvulsants | 3 | 2023 | 88 | 0.250 |
Why?
|
| Hospitalization | 4 | 2018 | 1292 | 0.240 |
Why?
|
| Warfarin | 3 | 2023 | 105 | 0.240 |
Why?
|
| Drug Prescriptions | 3 | 2020 | 168 | 0.240 |
Why?
|
| Community Health Services | 1 | 2005 | 120 | 0.230 |
Why?
|
| Communication | 2 | 2012 | 546 | 0.230 |
Why?
|
| Male | 22 | 2025 | 27772 | 0.220 |
Why?
|
| Cross-Sectional Studies | 9 | 2021 | 2382 | 0.220 |
Why?
|
| Anticoagulants | 4 | 2023 | 480 | 0.220 |
Why?
|
| Clonazepam | 1 | 2023 | 3 | 0.220 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2023 | 11 | 0.210 |
Why?
|
| Rivaroxaban | 2 | 2023 | 19 | 0.210 |
Why?
|
| Analgesics | 2 | 2021 | 96 | 0.210 |
Why?
|
| Dabigatran | 2 | 2023 | 20 | 0.210 |
Why?
|
| Retrospective Studies | 10 | 2025 | 6077 | 0.200 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 130 | 0.200 |
Why?
|
| Embolism | 1 | 2023 | 39 | 0.200 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 34 | 0.200 |
Why?
|
| Heart Failure | 3 | 2017 | 853 | 0.190 |
Why?
|
| Fractures, Bone | 2 | 2025 | 136 | 0.190 |
Why?
|
| Immunization | 1 | 2022 | 128 | 0.190 |
Why?
|
| Neuralgia | 1 | 2021 | 20 | 0.190 |
Why?
|
| Liver Diseases | 1 | 2023 | 137 | 0.190 |
Why?
|
| Administration, Oral | 4 | 2023 | 355 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 735 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 75 | 0.170 |
Why?
|
| Oxycodone | 2 | 2018 | 30 | 0.170 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2017 | 147 | 0.170 |
Why?
|
| Vaccination | 1 | 2022 | 335 | 0.160 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2019 | 7 | 0.160 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2021 | 119 | 0.160 |
Why?
|
| Cancer Pain | 1 | 2019 | 15 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 141 | 0.160 |
Why?
|
| Patient-Centered Care | 3 | 2016 | 246 | 0.160 |
Why?
|
| Program Development | 2 | 2018 | 203 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2017 | 64 | 0.150 |
Why?
|
| Geographic Mapping | 1 | 2018 | 6 | 0.150 |
Why?
|
| Medicare Part D | 4 | 2020 | 37 | 0.150 |
Why?
|
| Self Care | 1 | 2020 | 207 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2023 | 2376 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2011 | 1926 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2020 | 405 | 0.140 |
Why?
|
| Morphine | 1 | 2016 | 51 | 0.130 |
Why?
|
| Fentanyl | 1 | 2016 | 72 | 0.120 |
Why?
|
| Stroke Volume | 1 | 2017 | 314 | 0.120 |
Why?
|
| Prevalence | 4 | 2021 | 1254 | 0.120 |
Why?
|
| Delayed-Action Preparations | 3 | 2025 | 111 | 0.120 |
Why?
|
| Biological Products | 1 | 2016 | 90 | 0.120 |
Why?
|
| Brain Ischemia | 1 | 2019 | 399 | 0.120 |
Why?
|
| Hemorrhage | 3 | 2023 | 260 | 0.110 |
Why?
|
| Internet | 3 | 2012 | 448 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2018 | 683 | 0.110 |
Why?
|
| Biomedical Research | 2 | 2007 | 256 | 0.110 |
Why?
|
| Brain | 1 | 2021 | 1488 | 0.100 |
Why?
|
| Middle Aged | 8 | 2020 | 16330 | 0.100 |
Why?
|
| Videodisc Recording | 1 | 2012 | 8 | 0.100 |
Why?
|
| Community Pharmacy Services | 1 | 2012 | 13 | 0.100 |
Why?
|
| Interprofessional Relations | 2 | 2018 | 129 | 0.100 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2012 | 21 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 705 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 674 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2012 | 102 | 0.090 |
Why?
|
| Software Design | 1 | 2011 | 27 | 0.090 |
Why?
|
| Comorbidity | 3 | 2020 | 1078 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 1482 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 170 | 0.090 |
Why?
|
| Health Education | 1 | 2012 | 183 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2011 | 95 | 0.090 |
Why?
|
| Accidental Falls | 2 | 2025 | 124 | 0.090 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 64 | 0.090 |
Why?
|
| Patient Safety | 1 | 2012 | 238 | 0.080 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 453 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2025 | 805 | 0.080 |
Why?
|
| Sex Factors | 1 | 2011 | 935 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 25 | 0.080 |
Why?
|
| Ethics, Pharmacy | 1 | 2008 | 3 | 0.070 |
Why?
|
| Keratinocytes | 1 | 2008 | 63 | 0.070 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2008 | 64 | 0.070 |
Why?
|
| Drug Industry | 1 | 2008 | 39 | 0.070 |
Why?
|
| Tramadol | 2 | 2018 | 16 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 725 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2338 | 0.070 |
Why?
|
| Models, Statistical | 2 | 2005 | 299 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 515 | 0.070 |
Why?
|
| Urinary Tract Infections | 1 | 2007 | 80 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 237 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 140 | 0.060 |
Why?
|
| Information Storage and Retrieval | 1 | 2005 | 60 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 20 | 0.060 |
Why?
|
| Lorazepam | 1 | 2023 | 8 | 0.050 |
Why?
|
| Diazepam | 1 | 2023 | 10 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 398 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 3620 | 0.050 |
Why?
|
| Valproic Acid | 1 | 2023 | 26 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2023 | 98 | 0.050 |
Why?
|
| Risk Factors | 3 | 2020 | 4990 | 0.050 |
Why?
|
| South Dakota | 1 | 2002 | 4 | 0.050 |
Why?
|
| Mississippi | 1 | 2002 | 16 | 0.050 |
Why?
|
| Maine | 1 | 2002 | 18 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2005 | 814 | 0.050 |
Why?
|
| New York | 1 | 2002 | 134 | 0.050 |
Why?
|
| Medical Informatics | 2 | 2012 | 67 | 0.050 |
Why?
|
| Prognosis | 2 | 2005 | 1597 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 440 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 164 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 202 | 0.050 |
Why?
|
| Myocardial Ischemia | 1 | 2002 | 111 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2020 | 5285 | 0.040 |
Why?
|
| Societies, Pharmaceutical | 2 | 2012 | 2 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 1239 | 0.040 |
Why?
|
| Curriculum | 2 | 2018 | 560 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 77 | 0.040 |
Why?
|
| Narcotics | 1 | 2021 | 50 | 0.040 |
Why?
|
| Neuromuscular Agents | 1 | 2020 | 16 | 0.040 |
Why?
|
| Prescription Drug Misuse | 1 | 2020 | 20 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 154 | 0.040 |
Why?
|
| Pregnancy | 1 | 2007 | 2214 | 0.040 |
Why?
|
| Analgesia | 1 | 2020 | 30 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2020 | 72 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2020 | 61 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2019 | 40 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 454 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 137 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 212 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 180 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2018 | 69 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 61 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 279 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2018 | 151 | 0.040 |
Why?
|
| Ischemic Attack, Transient | 1 | 2018 | 90 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 364 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 159 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2018 | 327 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 717 | 0.030 |
Why?
|
| Oxymorphone | 1 | 2016 | 5 | 0.030 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 28 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 26 | 0.030 |
Why?
|
| Rhode Island | 1 | 2016 | 98 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2017 | 158 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2018 | 279 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2016 | 176 | 0.030 |
Why?
|
| Adult | 2 | 2012 | 15693 | 0.030 |
Why?
|
| Research Design | 2 | 2008 | 556 | 0.030 |
Why?
|
| Buprenorphine | 1 | 2016 | 181 | 0.030 |
Why?
|
| Pharmacology, Clinical | 1 | 2012 | 2 | 0.030 |
Why?
|
| Medication Reconciliation | 1 | 2012 | 13 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2012 | 115 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 863 | 0.020 |
Why?
|
| Cultural Diversity | 1 | 2012 | 52 | 0.020 |
Why?
|
| Depression | 1 | 2018 | 829 | 0.020 |
Why?
|
| Logistic Models | 2 | 2005 | 1235 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 202 | 0.020 |
Why?
|
| Geriatrics | 1 | 2010 | 41 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2012 | 342 | 0.020 |
Why?
|
| Teaching | 1 | 2010 | 152 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2010 | 212 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2012 | 418 | 0.020 |
Why?
|
| Confidentiality | 1 | 2008 | 52 | 0.020 |
Why?
|
| Disclosure | 1 | 2008 | 51 | 0.020 |
Why?
|
| Conflict of Interest | 1 | 2008 | 36 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2007 | 57 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2007 | 92 | 0.020 |
Why?
|
| Organizational Innovation | 1 | 2007 | 81 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2007 | 101 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 166 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2007 | 470 | 0.020 |
Why?
|
| Bias | 1 | 2004 | 108 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 487 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 115 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 554 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2517 | 0.010 |
Why?
|
| Hypertension | 1 | 2005 | 570 | 0.010 |
Why?
|